BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL
Part of paid clinical trials in Duarte, California.
- Sponsor
- PeproMene Bio, Inc.
- Study ID
- NCT05370430
- Phase
- PHASE1
- Status
- Recruiting
Conditions
- Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- BAFFR-CAR T cells — BIOLOGICALFirst-in-human trial examining the safety and preliminary efficacy of BAFFR-CAR T cells in participants with r/r B-NHL
Study Details
A Phase 1 Study Evaluating BAFFR-targeting CAR T Cells for Patients with Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma (B-NHL)
Key Dates
- Start date
- Jun 13, 2022
- Status verified
- Nov 2025
- Primary completion
- Jul 13, 2027
- Completion
- Jun 13, 2028
Study Design
- Enrollment
- 36 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: B-cell activating factor receptor-Chimeric antigen receptor T cells [BAFFR-CAR T cells]BAFFR-CAR T cells in participants with r/r B-NHL
Primary Outcome Measure
Incidence of adverse events [ Time Frame: Up to 1 year post treatment ]
Central Contacts
- Hazel (Ting-Ying) Cheng, PhD714-599-8077
- DeShaun Noakes, M.S.760-533-4023
Locations (6)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| City of Hope Medical Center | Duarte | California | 91010 | Elizabeth Budde, MD Qing Liu-Michael, PhD |
| Stanford University | Stanford | California | 94305 | Matthew Frank (PRINCIPAL_INVESTIGATOR) |
| University of Kansas Hospital | Kansas City | Kansas | 66160 | |
| University of Minnesota | Minneapolis | Minnesota | 55455 | |
| Atrium Health Levine Cancer Institute - Morehead | Charlotte | North Carolina | 28204 | |
| Providence Swedish Cancer Institute | Seattle | Washington | 98104 |